The Key Players Global Hepatitis Drugs Market 2015-2019, According to a New Study on ASDReports

Monday 14 December 2015, Amsterdam

Market Research Report Press Release The report, now available on ASDReports, recognizes the following companies as the key players in the Global Hepatitis Drugs Market: F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis and Vertex Pharmaceuticals

Other Prominent Vendors in the market are: Abbvie, Achillion Pharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies and Mitsubishi Tanabe Pharma

Commenting on the report, an analyst said: “The global hepatitis drugs market in emerging countries such as India, Brazil, China, and Russia is expected to grow at a rapid pace during the forecast period owing to an increase in patient population and public awareness about hepatitis. Drug manufacturers focus on these countries with the motive of launching new products and penetrating these markets.”

According to the report, early detection of hepatitis is important in reducing the chances of developing liver infections, which can prevent extensive liver damage. Various government and non-government organizations organize awareness campaigns and other programs to educate people about the disease and therapeutic measures available.

Further, the report states that the patent expiration of approved drugs is expected to have an adverse impact on the market, slowing down market growth during the forecast period.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Global Hepatitis Drugs Market 2015-2019

Global Hepatitis Drugs Market 2015-2019

Publish date : December 2015
Report code : ASDR-240136
Pages : 118 Media contact: S. Koopman - Marketing and Communications / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E :

 back to News